Efficacy and Safety of Apremilast in Patients With Recalcitrant Cutaneous Dermatomyositis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Apremilast in Recalcitrant Cutaneous Dermatomyositis: A Nonrandomized Controlled Trial
JAMA Dermatol 2022 Oct 05;[EPub Ahead of Print], C Bitar, T Ninh, K Brag, S Foutouhi, S Radosta, J Meyers, M Baddoo, D Liu, B Stumpf, PW Harms, NS Saba, E BohFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.